Trump’s tariffs may prompt firms to reassess investments, but the sector’s long-term growth outlook is unlikely to change, say analysts
In this series, The Business Times delves into the state of Singapore’s biotech scene, exploring a key challenge: converting its world-class research and development output into commercial victories.
While our first story looked at the reasons behind why few home-grown companies are listing on the Singapore Exchange, this instalment looks upstream and finds a more vibrant picture as international biotech venture capital firms head to Singapore. Upcoming stories will explore the macroeconomic headwinds facing the sector and the future direction of the industry.
[SINGAPORE] International biotech venture capital (VC) firms are flocking to Singapore, drawn by the Asia-Pacific region’s growing life sciences sector, with one more European VC confirmed to set up operations before year-end.
